Novo Nordisk
NVO
$79.83
Share price
-1.51%
Change (1 day)
-43.13%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Market capitalization of Novo Nordisk (NVO)
Market cap: $356.65 Billion USD
As of June 2025 Novo Nordisk has a market cap of $356.65 Billion USD. This makes Novo Nordisk the world's 24th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Novo Nordisk from 1996 to 2025
End of year Market Cap
| Year | Marketcap | Change |
|---|---|---|
| 2025 | $356.65 B | -7.13% |
| 2024 | $384.05 B | -16.73% |
| 2023 | $461.21 B | 51.46% |
| 2022 | $304.50 B | 19.38% |
| 2021 | $255.07 B | 56.42% |
| 2020 | $163.07 B | 17.22% |
| 2019 | $139.12 B | 24.43% |
| 2018 | $111.80 B | -14.74% |
| 2017 | $131.12 B | 39.24% |
| 2016 | $94.17 B | -38.17% |
| 2015 | $152.30 B | 35.23% |
| 2014 | $112.62 B | 11.3% |
| 2013 | $101.18 B | 11.24% |
| 2012 | $90.96 B | 36.37% |
| 2011 | $66.70 B | -1.24% |
| 2010 | $67.54 B | 66.85% |
| 2009 | $40.48 B | 24.25% |
| 2008 | $32.58 B | -22.36% |
| 2007 | $41.96 B | 58.17% |
| 2006 | $26.53 B | 45.63% |
| 2005 | $18.21 B | 1.1% |
| 2004 | $18.02 B | 27.41% |
| 2003 | $14.14 B | 40.56% |
| 2002 | $10.06 B | -27.62% |
| 2001 | $13.90 B | 12.46% |
| 2000 | $12.36 B | 34.85% |
| 1999 | $9.16 B | -4.91% |
| 1998 | $9.64 B | -10.92% |
| 1997 | $10.82 B | 54.34% |
| 1996 | $7.01 B |
End of Day market cap according to different sources
On Jun 15th, 2025 the market cap of Novo Nordisk was reported to be:
$356.44 Billion USD
$356.65 Billion USD
Market capitalization for similar companies or competitors
| Name | Marketcap | Market cap differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $139.51 B | -60.88% | 🇺🇸 USA |
 Eli Lilly LLY | $735.56 B | 106.24% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $101.24 B | -71.61% | 🇺🇸 USA |
 Sanofi SNY | $122.85 B | -65.55% | 🇫🇷 France |